nodes	percent_of_prediction	percent_of_DWPC	metapath
Prednisone—prostate cancer—urinary bladder cancer	0.632	1	CtDrD
Prednisone—ABCB1—Mitomycin—urinary bladder cancer	0.0502	0.258	CbGbCtD
Prednisone—SLCO1A2—Methotrexate—urinary bladder cancer	0.0252	0.13	CbGbCtD
Prednisone—ALB—Fluorouracil—urinary bladder cancer	0.0236	0.122	CbGbCtD
Prednisone—CYP3A4—Thiotepa—urinary bladder cancer	0.0228	0.117	CbGbCtD
Prednisone—ABCB1—Gemcitabine—urinary bladder cancer	0.0144	0.0743	CbGbCtD
Prednisone—ALB—Methotrexate—urinary bladder cancer	0.013	0.067	CbGbCtD
Prednisone—ABCB1—Cisplatin—urinary bladder cancer	0.0105	0.054	CbGbCtD
Prednisone—ABCB1—Etoposide—urinary bladder cancer	0.0103	0.0531	CbGbCtD
Prednisone—ABCB1—Doxorubicin—urinary bladder cancer	0.00704	0.0362	CbGbCtD
Prednisone—ABCB1—Methotrexate—urinary bladder cancer	0.00682	0.0351	CbGbCtD
Prednisone—CYP3A4—Etoposide—urinary bladder cancer	0.00618	0.0318	CbGbCtD
Prednisone—HSD11B1—prostate gland—urinary bladder cancer	0.00428	0.109	CbGeAlD
Prednisone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00422	0.0217	CbGbCtD
Prednisone—HSD11B1—seminal vesicle—urinary bladder cancer	0.00362	0.0926	CbGeAlD
Prednisone—HSD11B1—smooth muscle tissue—urinary bladder cancer	0.00303	0.0775	CbGeAlD
Prednisone—HSD11B1—renal system—urinary bladder cancer	0.00292	0.0746	CbGeAlD
Prednisone—CYP2C19—urine—urinary bladder cancer	0.00289	0.0739	CbGeAlD
Prednisone—HSD11B1—urethra—urinary bladder cancer	0.00287	0.0733	CbGeAlD
Prednisone—HSD11B1—female reproductive system—urinary bladder cancer	0.00234	0.0598	CbGeAlD
Prednisone—NR3C1—urine—urinary bladder cancer	0.00226	0.0577	CbGeAlD
Prednisone—HSD11B1—vagina—urinary bladder cancer	0.00211	0.0541	CbGeAlD
Prednisone—CYP3A4—urine—urinary bladder cancer	0.00171	0.0437	CbGeAlD
Prednisone—HSD11B1—lymph node—urinary bladder cancer	0.00137	0.035	CbGeAlD
Prednisone—SLCO1A2—renal system—urinary bladder cancer	0.000882	0.0226	CbGeAlD
Prednisone—NR3C1—prostate gland—urinary bladder cancer	0.00081	0.0207	CbGeAlD
Prednisone—NR3C1—seminal vesicle—urinary bladder cancer	0.000685	0.0175	CbGeAlD
Prednisone—NR3C1—epithelium—urinary bladder cancer	0.000595	0.0152	CbGeAlD
Prednisone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000574	0.0147	CbGeAlD
Prednisone—NR3C1—renal system—urinary bladder cancer	0.000552	0.0141	CbGeAlD
Prednisone—NR3C1—urethra—urinary bladder cancer	0.000542	0.0139	CbGeAlD
Prednisone—CYP2C19—vagina—urinary bladder cancer	0.000512	0.0131	CbGeAlD
Prednisone—NR3C1—female reproductive system—urinary bladder cancer	0.000442	0.0113	CbGeAlD
Prednisone—ABCB1—prostate gland—urinary bladder cancer	0.000434	0.0111	CbGeAlD
Prednisone—CYP3A4—renal system—urinary bladder cancer	0.000418	0.0107	CbGeAlD
Prednisone—ALB—lymph node—urinary bladder cancer	0.000411	0.0105	CbGeAlD
Prednisone—NR3C1—vagina—urinary bladder cancer	0.0004	0.0102	CbGeAlD
Prednisone—ABCB1—seminal vesicle—urinary bladder cancer	0.000367	0.00938	CbGeAlD
Prednisone—CYP3A4—female reproductive system—urinary bladder cancer	0.000334	0.00856	CbGeAlD
Prednisone—ABCB1—epithelium—urinary bladder cancer	0.000319	0.00815	CbGeAlD
Prednisone—ABCB1—renal system—urinary bladder cancer	0.000296	0.00756	CbGeAlD
Prednisone—ABCB1—urethra—urinary bladder cancer	0.00029	0.00743	CbGeAlD
Prednisone—NR3C1—lymph node—urinary bladder cancer	0.000259	0.00662	CbGeAlD
Prednisone—ABCB1—female reproductive system—urinary bladder cancer	0.000237	0.00606	CbGeAlD
Prednisone—ABCB1—vagina—urinary bladder cancer	0.000214	0.00548	CbGeAlD
Prednisone—ABCB1—lymph node—urinary bladder cancer	0.000139	0.00354	CbGeAlD
Prednisone—Infection—Etoposide—urinary bladder cancer	8.41e-05	0.000782	CcSEcCtD
Prednisone—Abdominal distension—Epirubicin—urinary bladder cancer	8.4e-05	0.000781	CcSEcCtD
Prednisone—Neutropenia—Methotrexate—urinary bladder cancer	8.34e-05	0.000776	CcSEcCtD
Prednisone—Pruritus—Thiotepa—urinary bladder cancer	8.34e-05	0.000776	CcSEcCtD
Prednisone—Paraesthesia—Cisplatin—urinary bladder cancer	8.3e-05	0.000772	CcSEcCtD
Prednisone—Tachycardia—Etoposide—urinary bladder cancer	8.26e-05	0.000768	CcSEcCtD
Prednisone—Skin disorder—Etoposide—urinary bladder cancer	8.22e-05	0.000765	CcSEcCtD
Prednisone—Erectile dysfunction—Methotrexate—urinary bladder cancer	8.21e-05	0.000764	CcSEcCtD
Prednisone—Dry skin—Doxorubicin—urinary bladder cancer	8.19e-05	0.000762	CcSEcCtD
Prednisone—Hyperhidrosis—Etoposide—urinary bladder cancer	8.18e-05	0.000761	CcSEcCtD
Prednisone—Pancreatitis—Epirubicin—urinary bladder cancer	8.18e-05	0.000761	CcSEcCtD
Prednisone—Feeling abnormal—Gemcitabine—urinary bladder cancer	8.17e-05	0.00076	CcSEcCtD
Prednisone—Hypokalaemia—Doxorubicin—urinary bladder cancer	8.13e-05	0.000756	CcSEcCtD
Prednisone—Anorexia—Etoposide—urinary bladder cancer	8.07e-05	0.000751	CcSEcCtD
Prednisone—Diarrhoea—Thiotepa—urinary bladder cancer	8.06e-05	0.00075	CcSEcCtD
Prednisone—Decreased appetite—Cisplatin—urinary bladder cancer	8.03e-05	0.000747	CcSEcCtD
Prednisone—Feeling abnormal—Fluorouracil—urinary bladder cancer	8.03e-05	0.000747	CcSEcCtD
Prednisone—Depression—Methotrexate—urinary bladder cancer	7.93e-05	0.000737	CcSEcCtD
Prednisone—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	7.88e-05	0.000733	CcSEcCtD
Prednisone—Muscular weakness—Doxorubicin—urinary bladder cancer	7.88e-05	0.000733	CcSEcCtD
Prednisone—Body temperature increased—Gemcitabine—urinary bladder cancer	7.84e-05	0.000729	CcSEcCtD
Prednisone—Neutropenia—Epirubicin—urinary bladder cancer	7.8e-05	0.000726	CcSEcCtD
Prednisone—Dizziness—Thiotepa—urinary bladder cancer	7.79e-05	0.000725	CcSEcCtD
Prednisone—Abdominal distension—Doxorubicin—urinary bladder cancer	7.77e-05	0.000723	CcSEcCtD
Prednisone—Urticaria—Fluorouracil—urinary bladder cancer	7.74e-05	0.00072	CcSEcCtD
Prednisone—Body temperature increased—Fluorouracil—urinary bladder cancer	7.71e-05	0.000717	CcSEcCtD
Prednisone—Feeling abnormal—Cisplatin—urinary bladder cancer	7.61e-05	0.000708	CcSEcCtD
Prednisone—Paraesthesia—Etoposide—urinary bladder cancer	7.6e-05	0.000707	CcSEcCtD
Prednisone—Weight increased—Epirubicin—urinary bladder cancer	7.59e-05	0.000706	CcSEcCtD
Prednisone—Pancreatitis—Doxorubicin—urinary bladder cancer	7.57e-05	0.000704	CcSEcCtD
Prednisone—Weight decreased—Epirubicin—urinary bladder cancer	7.55e-05	0.000702	CcSEcCtD
Prednisone—Hyperglycaemia—Epirubicin—urinary bladder cancer	7.53e-05	0.0007	CcSEcCtD
Prednisone—Vomiting—Thiotepa—urinary bladder cancer	7.49e-05	0.000697	CcSEcCtD
Prednisone—Rash—Thiotepa—urinary bladder cancer	7.43e-05	0.000691	CcSEcCtD
Prednisone—Dermatitis—Thiotepa—urinary bladder cancer	7.42e-05	0.000691	CcSEcCtD
Prednisone—Headache—Thiotepa—urinary bladder cancer	7.38e-05	0.000687	CcSEcCtD
Prednisone—Decreased appetite—Etoposide—urinary bladder cancer	7.36e-05	0.000684	CcSEcCtD
Prednisone—Body temperature increased—Cisplatin—urinary bladder cancer	7.3e-05	0.000679	CcSEcCtD
Prednisone—Fatigue—Etoposide—urinary bladder cancer	7.3e-05	0.000679	CcSEcCtD
Prednisone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	7.29e-05	0.000678	CcSEcCtD
Prednisone—Constipation—Etoposide—urinary bladder cancer	7.24e-05	0.000673	CcSEcCtD
Prednisone—Neutropenia—Doxorubicin—urinary bladder cancer	7.22e-05	0.000672	CcSEcCtD
Prednisone—Hypersensitivity—Fluorouracil—urinary bladder cancer	7.18e-05	0.000668	CcSEcCtD
Prednisone—Haemoglobin—Methotrexate—urinary bladder cancer	7.17e-05	0.000667	CcSEcCtD
Prednisone—Haemorrhage—Methotrexate—urinary bladder cancer	7.14e-05	0.000664	CcSEcCtD
Prednisone—Asthenia—Gemcitabine—urinary bladder cancer	7.11e-05	0.000662	CcSEcCtD
Prednisone—Weight increased—Doxorubicin—urinary bladder cancer	7.03e-05	0.000654	CcSEcCtD
Prednisone—Pruritus—Gemcitabine—urinary bladder cancer	7.01e-05	0.000652	CcSEcCtD
Prednisone—Nausea—Thiotepa—urinary bladder cancer	7e-05	0.000651	CcSEcCtD
Prednisone—Weight decreased—Doxorubicin—urinary bladder cancer	6.98e-05	0.00065	CcSEcCtD
Prednisone—Feeling abnormal—Etoposide—urinary bladder cancer	6.98e-05	0.000649	CcSEcCtD
Prednisone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	6.96e-05	0.000648	CcSEcCtD
Prednisone—Gastrointestinal pain—Etoposide—urinary bladder cancer	6.92e-05	0.000644	CcSEcCtD
Prednisone—Pruritus—Fluorouracil—urinary bladder cancer	6.9e-05	0.000641	CcSEcCtD
Prednisone—Hypersensitivity—Cisplatin—urinary bladder cancer	6.81e-05	0.000633	CcSEcCtD
Prednisone—Bradycardia—Epirubicin—urinary bladder cancer	6.8e-05	0.000632	CcSEcCtD
Prednisone—Diarrhoea—Gemcitabine—urinary bladder cancer	6.78e-05	0.000631	CcSEcCtD
Prednisone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	6.75e-05	0.000628	CcSEcCtD
Prednisone—Urticaria—Etoposide—urinary bladder cancer	6.72e-05	0.000626	CcSEcCtD
Prednisone—Haemoglobin—Epirubicin—urinary bladder cancer	6.71e-05	0.000624	CcSEcCtD
Prednisone—Abdominal pain—Etoposide—urinary bladder cancer	6.69e-05	0.000622	CcSEcCtD
Prednisone—Body temperature increased—Etoposide—urinary bladder cancer	6.69e-05	0.000622	CcSEcCtD
Prednisone—Haemorrhage—Epirubicin—urinary bladder cancer	6.68e-05	0.000621	CcSEcCtD
Prednisone—Eye disorder—Methotrexate—urinary bladder cancer	6.67e-05	0.00062	CcSEcCtD
Prednisone—Diarrhoea—Fluorouracil—urinary bladder cancer	6.67e-05	0.00062	CcSEcCtD
Prednisone—Asthenia—Cisplatin—urinary bladder cancer	6.63e-05	0.000617	CcSEcCtD
Prednisone—Connective tissue disorder—Epirubicin—urinary bladder cancer	6.56e-05	0.000611	CcSEcCtD
Prednisone—Angiopathy—Methotrexate—urinary bladder cancer	6.48e-05	0.000602	CcSEcCtD
Prednisone—Immune system disorder—Methotrexate—urinary bladder cancer	6.45e-05	0.0006	CcSEcCtD
Prednisone—Dizziness—Fluorouracil—urinary bladder cancer	6.45e-05	0.0006	CcSEcCtD
Prednisone—Diarrhoea—Cisplatin—urinary bladder cancer	6.32e-05	0.000588	CcSEcCtD
Prednisone—Alopecia—Methotrexate—urinary bladder cancer	6.31e-05	0.000587	CcSEcCtD
Prednisone—Vomiting—Gemcitabine—urinary bladder cancer	6.3e-05	0.000586	CcSEcCtD
Prednisone—Bradycardia—Doxorubicin—urinary bladder cancer	6.29e-05	0.000585	CcSEcCtD
Prednisone—Mental disorder—Methotrexate—urinary bladder cancer	6.25e-05	0.000582	CcSEcCtD
Prednisone—Rash—Gemcitabine—urinary bladder cancer	6.25e-05	0.000581	CcSEcCtD
Prednisone—Dermatitis—Gemcitabine—urinary bladder cancer	6.24e-05	0.000581	CcSEcCtD
Prednisone—Eye disorder—Epirubicin—urinary bladder cancer	6.24e-05	0.000581	CcSEcCtD
Prednisone—Hypersensitivity—Etoposide—urinary bladder cancer	6.24e-05	0.00058	CcSEcCtD
Prednisone—Malnutrition—Methotrexate—urinary bladder cancer	6.21e-05	0.000578	CcSEcCtD
Prednisone—Erythema—Methotrexate—urinary bladder cancer	6.21e-05	0.000578	CcSEcCtD
Prednisone—Haemoglobin—Doxorubicin—urinary bladder cancer	6.21e-05	0.000578	CcSEcCtD
Prednisone—Headache—Gemcitabine—urinary bladder cancer	6.21e-05	0.000578	CcSEcCtD
Prednisone—Flushing—Epirubicin—urinary bladder cancer	6.2e-05	0.000577	CcSEcCtD
Prednisone—Vomiting—Fluorouracil—urinary bladder cancer	6.2e-05	0.000576	CcSEcCtD
Prednisone—Haemorrhage—Doxorubicin—urinary bladder cancer	6.18e-05	0.000575	CcSEcCtD
Prednisone—Rash—Fluorouracil—urinary bladder cancer	6.15e-05	0.000572	CcSEcCtD
Prednisone—Dermatitis—Fluorouracil—urinary bladder cancer	6.14e-05	0.000571	CcSEcCtD
Prednisone—Headache—Fluorouracil—urinary bladder cancer	6.11e-05	0.000568	CcSEcCtD
Prednisone—Asthenia—Etoposide—urinary bladder cancer	6.07e-05	0.000565	CcSEcCtD
Prednisone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	6.07e-05	0.000565	CcSEcCtD
Prednisone—Angiopathy—Epirubicin—urinary bladder cancer	6.06e-05	0.000564	CcSEcCtD
Prednisone—Immune system disorder—Epirubicin—urinary bladder cancer	6.03e-05	0.000561	CcSEcCtD
Prednisone—Pruritus—Etoposide—urinary bladder cancer	5.99e-05	0.000557	CcSEcCtD
Prednisone—Arrhythmia—Epirubicin—urinary bladder cancer	5.97e-05	0.000555	CcSEcCtD
Prednisone—Alopecia—Epirubicin—urinary bladder cancer	5.9e-05	0.000549	CcSEcCtD
Prednisone—Nausea—Gemcitabine—urinary bladder cancer	5.89e-05	0.000548	CcSEcCtD
Prednisone—Vomiting—Cisplatin—urinary bladder cancer	5.87e-05	0.000546	CcSEcCtD
Prednisone—Vision blurred—Methotrexate—urinary bladder cancer	5.85e-05	0.000545	CcSEcCtD
Prednisone—Mental disorder—Epirubicin—urinary bladder cancer	5.85e-05	0.000544	CcSEcCtD
Prednisone—Rash—Cisplatin—urinary bladder cancer	5.83e-05	0.000542	CcSEcCtD
Prednisone—Dermatitis—Cisplatin—urinary bladder cancer	5.82e-05	0.000541	CcSEcCtD
Prednisone—Malnutrition—Epirubicin—urinary bladder cancer	5.81e-05	0.000541	CcSEcCtD
Prednisone—Erythema—Epirubicin—urinary bladder cancer	5.81e-05	0.000541	CcSEcCtD
Prednisone—Diarrhoea—Etoposide—urinary bladder cancer	5.79e-05	0.000539	CcSEcCtD
Prednisone—Nausea—Fluorouracil—urinary bladder cancer	5.79e-05	0.000539	CcSEcCtD
Prednisone—Eye disorder—Doxorubicin—urinary bladder cancer	5.78e-05	0.000537	CcSEcCtD
Prednisone—Ill-defined disorder—Methotrexate—urinary bladder cancer	5.76e-05	0.000536	CcSEcCtD
Prednisone—Anaemia—Methotrexate—urinary bladder cancer	5.74e-05	0.000534	CcSEcCtD
Prednisone—Flushing—Doxorubicin—urinary bladder cancer	5.74e-05	0.000534	CcSEcCtD
Prednisone—Angiopathy—Doxorubicin—urinary bladder cancer	5.61e-05	0.000522	CcSEcCtD
Prednisone—Malaise—Methotrexate—urinary bladder cancer	5.6e-05	0.000521	CcSEcCtD
Prednisone—Dizziness—Etoposide—urinary bladder cancer	5.6e-05	0.000521	CcSEcCtD
Prednisone—Immune system disorder—Doxorubicin—urinary bladder cancer	5.58e-05	0.000519	CcSEcCtD
Prednisone—Vertigo—Methotrexate—urinary bladder cancer	5.58e-05	0.000519	CcSEcCtD
Prednisone—Arrhythmia—Doxorubicin—urinary bladder cancer	5.52e-05	0.000514	CcSEcCtD
Prednisone—Nausea—Cisplatin—urinary bladder cancer	5.49e-05	0.000511	CcSEcCtD
Prednisone—Vision blurred—Epirubicin—urinary bladder cancer	5.48e-05	0.00051	CcSEcCtD
Prednisone—Alopecia—Doxorubicin—urinary bladder cancer	5.46e-05	0.000508	CcSEcCtD
Prednisone—Mental disorder—Doxorubicin—urinary bladder cancer	5.41e-05	0.000504	CcSEcCtD
Prednisone—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.39e-05	0.000502	CcSEcCtD
Prednisone—Convulsion—Methotrexate—urinary bladder cancer	5.38e-05	0.000501	CcSEcCtD
Prednisone—Vomiting—Etoposide—urinary bladder cancer	5.38e-05	0.000501	CcSEcCtD
Prednisone—Erythema—Doxorubicin—urinary bladder cancer	5.38e-05	0.0005	CcSEcCtD
Prednisone—Malnutrition—Doxorubicin—urinary bladder cancer	5.38e-05	0.0005	CcSEcCtD
Prednisone—Anaemia—Epirubicin—urinary bladder cancer	5.37e-05	0.0005	CcSEcCtD
Prednisone—Agitation—Epirubicin—urinary bladder cancer	5.34e-05	0.000497	CcSEcCtD
Prednisone—Rash—Etoposide—urinary bladder cancer	5.34e-05	0.000496	CcSEcCtD
Prednisone—Dermatitis—Etoposide—urinary bladder cancer	5.33e-05	0.000496	CcSEcCtD
Prednisone—Headache—Etoposide—urinary bladder cancer	5.3e-05	0.000493	CcSEcCtD
Prednisone—Myalgia—Methotrexate—urinary bladder cancer	5.29e-05	0.000492	CcSEcCtD
Prednisone—Arthralgia—Methotrexate—urinary bladder cancer	5.29e-05	0.000492	CcSEcCtD
Prednisone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.25e-05	0.000489	CcSEcCtD
Prednisone—Malaise—Epirubicin—urinary bladder cancer	5.24e-05	0.000488	CcSEcCtD
Prednisone—Discomfort—Methotrexate—urinary bladder cancer	5.23e-05	0.000486	CcSEcCtD
Prednisone—Vertigo—Epirubicin—urinary bladder cancer	5.22e-05	0.000486	CcSEcCtD
Prednisone—Syncope—Epirubicin—urinary bladder cancer	5.21e-05	0.000485	CcSEcCtD
Prednisone—Loss of consciousness—Epirubicin—urinary bladder cancer	5.11e-05	0.000475	CcSEcCtD
Prednisone—Anaphylactic shock—Methotrexate—urinary bladder cancer	5.07e-05	0.000472	CcSEcCtD
Prednisone—Vision blurred—Doxorubicin—urinary bladder cancer	5.07e-05	0.000472	CcSEcCtD
Prednisone—Convulsion—Epirubicin—urinary bladder cancer	5.04e-05	0.000469	CcSEcCtD
Prednisone—Infection—Methotrexate—urinary bladder cancer	5.04e-05	0.000469	CcSEcCtD
Prednisone—Nausea—Etoposide—urinary bladder cancer	5.03e-05	0.000468	CcSEcCtD
Prednisone—Hypertension—Epirubicin—urinary bladder cancer	5.02e-05	0.000467	CcSEcCtD
Prednisone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.99e-05	0.000464	CcSEcCtD
Prednisone—Nervous system disorder—Methotrexate—urinary bladder cancer	4.97e-05	0.000463	CcSEcCtD
Prednisone—Anaemia—Doxorubicin—urinary bladder cancer	4.97e-05	0.000463	CcSEcCtD
Prednisone—Arthralgia—Epirubicin—urinary bladder cancer	4.95e-05	0.00046	CcSEcCtD
Prednisone—Myalgia—Epirubicin—urinary bladder cancer	4.95e-05	0.00046	CcSEcCtD
Prednisone—Agitation—Doxorubicin—urinary bladder cancer	4.94e-05	0.00046	CcSEcCtD
Prednisone—Anxiety—Epirubicin—urinary bladder cancer	4.93e-05	0.000459	CcSEcCtD
Prednisone—Skin disorder—Methotrexate—urinary bladder cancer	4.92e-05	0.000458	CcSEcCtD
Prednisone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.92e-05	0.000457	CcSEcCtD
Prednisone—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.9e-05	0.000456	CcSEcCtD
Prednisone—Discomfort—Epirubicin—urinary bladder cancer	4.89e-05	0.000455	CcSEcCtD
Prednisone—Malaise—Doxorubicin—urinary bladder cancer	4.85e-05	0.000451	CcSEcCtD
Prednisone—Vertigo—Doxorubicin—urinary bladder cancer	4.83e-05	0.00045	CcSEcCtD
Prednisone—Anorexia—Methotrexate—urinary bladder cancer	4.83e-05	0.00045	CcSEcCtD
Prednisone—Syncope—Doxorubicin—urinary bladder cancer	4.82e-05	0.000449	CcSEcCtD
Prednisone—Oedema—Epirubicin—urinary bladder cancer	4.74e-05	0.000441	CcSEcCtD
Prednisone—Anaphylactic shock—Epirubicin—urinary bladder cancer	4.74e-05	0.000441	CcSEcCtD
Prednisone—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.73e-05	0.00044	CcSEcCtD
Prednisone—Infection—Epirubicin—urinary bladder cancer	4.71e-05	0.000439	CcSEcCtD
Prednisone—Shock—Epirubicin—urinary bladder cancer	4.67e-05	0.000434	CcSEcCtD
Prednisone—Convulsion—Doxorubicin—urinary bladder cancer	4.66e-05	0.000434	CcSEcCtD
Prednisone—Nervous system disorder—Epirubicin—urinary bladder cancer	4.65e-05	0.000433	CcSEcCtD
Prednisone—Hypertension—Doxorubicin—urinary bladder cancer	4.64e-05	0.000432	CcSEcCtD
Prednisone—Tachycardia—Epirubicin—urinary bladder cancer	4.63e-05	0.000431	CcSEcCtD
Prednisone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.62e-05	0.00043	CcSEcCtD
Prednisone—Skin disorder—Epirubicin—urinary bladder cancer	4.61e-05	0.000429	CcSEcCtD
Prednisone—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.59e-05	0.000427	CcSEcCtD
Prednisone—Insomnia—Methotrexate—urinary bladder cancer	4.59e-05	0.000427	CcSEcCtD
Prednisone—Arthralgia—Doxorubicin—urinary bladder cancer	4.58e-05	0.000426	CcSEcCtD
Prednisone—Myalgia—Doxorubicin—urinary bladder cancer	4.58e-05	0.000426	CcSEcCtD
Prednisone—Anxiety—Doxorubicin—urinary bladder cancer	4.56e-05	0.000425	CcSEcCtD
Prednisone—Paraesthesia—Methotrexate—urinary bladder cancer	4.55e-05	0.000424	CcSEcCtD
Prednisone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.55e-05	0.000423	CcSEcCtD
Prednisone—Discomfort—Doxorubicin—urinary bladder cancer	4.53e-05	0.000421	CcSEcCtD
Prednisone—Anorexia—Epirubicin—urinary bladder cancer	4.52e-05	0.000421	CcSEcCtD
Prednisone—Dyspepsia—Methotrexate—urinary bladder cancer	4.46e-05	0.000415	CcSEcCtD
Prednisone—Decreased appetite—Methotrexate—urinary bladder cancer	4.41e-05	0.00041	CcSEcCtD
Prednisone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	4.39e-05	0.000408	CcSEcCtD
Prednisone—Oedema—Doxorubicin—urinary bladder cancer	4.39e-05	0.000408	CcSEcCtD
Prednisone—Fatigue—Methotrexate—urinary bladder cancer	4.37e-05	0.000407	CcSEcCtD
Prednisone—Infection—Doxorubicin—urinary bladder cancer	4.36e-05	0.000406	CcSEcCtD
Prednisone—ALB—Platelet degranulation—IGF1—urinary bladder cancer	4.33e-05	0.00163	CbGpPWpGaD
Prednisone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.32e-05	0.000402	CcSEcCtD
Prednisone—Shock—Doxorubicin—urinary bladder cancer	4.32e-05	0.000402	CcSEcCtD
Prednisone—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.31e-05	0.000401	CcSEcCtD
Prednisone—Insomnia—Epirubicin—urinary bladder cancer	4.29e-05	0.000399	CcSEcCtD
Prednisone—Tachycardia—Doxorubicin—urinary bladder cancer	4.28e-05	0.000399	CcSEcCtD
Prednisone—Skin disorder—Doxorubicin—urinary bladder cancer	4.26e-05	0.000397	CcSEcCtD
Prednisone—Paraesthesia—Epirubicin—urinary bladder cancer	4.26e-05	0.000396	CcSEcCtD
Prednisone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.24e-05	0.000395	CcSEcCtD
Prednisone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	4.21e-05	0.00158	CbGpPWpGaD
Prednisone—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	4.2e-05	0.00157	CbGpPWpGaD
Prednisone—Anorexia—Doxorubicin—urinary bladder cancer	4.19e-05	0.000389	CcSEcCtD
Prednisone—Feeling abnormal—Methotrexate—urinary bladder cancer	4.18e-05	0.000389	CcSEcCtD
Prednisone—Dyspepsia—Epirubicin—urinary bladder cancer	4.18e-05	0.000389	CcSEcCtD
Prednisone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.15e-05	0.000386	CcSEcCtD
Prednisone—Danazol—ESR1—urinary bladder cancer	4.14e-05	0.467	CrCbGaD
Prednisone—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	4.13e-05	0.00155	CbGpPWpGaD
Prednisone—Decreased appetite—Epirubicin—urinary bladder cancer	4.12e-05	0.000384	CcSEcCtD
Prednisone—Fatigue—Epirubicin—urinary bladder cancer	4.09e-05	0.000381	CcSEcCtD
Prednisone—SLCO1A2—Metabolism—UGT2B7—urinary bladder cancer	4.09e-05	0.00153	CbGpPWpGaD
Prednisone—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	4.09e-05	0.00153	CbGpPWpGaD
Prednisone—Constipation—Epirubicin—urinary bladder cancer	4.06e-05	0.000377	CcSEcCtD
Prednisone—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.04e-05	0.00152	CbGpPWpGaD
Prednisone—Urticaria—Methotrexate—urinary bladder cancer	4.03e-05	0.000375	CcSEcCtD
Prednisone—Body temperature increased—Methotrexate—urinary bladder cancer	4.01e-05	0.000373	CcSEcCtD
Prednisone—Abdominal pain—Methotrexate—urinary bladder cancer	4.01e-05	0.000373	CcSEcCtD
Prednisone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4e-05	0.000372	CcSEcCtD
Prednisone—Insomnia—Doxorubicin—urinary bladder cancer	3.97e-05	0.000369	CcSEcCtD
Prednisone—Paraesthesia—Doxorubicin—urinary bladder cancer	3.94e-05	0.000367	CcSEcCtD
Prednisone—Feeling abnormal—Epirubicin—urinary bladder cancer	3.91e-05	0.000364	CcSEcCtD
Prednisone—ALB—Folate Metabolism—IL2—urinary bladder cancer	3.89e-05	0.00146	CbGpPWpGaD
Prednisone—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	3.88e-05	0.00146	CbGpPWpGaD
Prednisone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.88e-05	0.000361	CcSEcCtD
Prednisone—Dyspepsia—Doxorubicin—urinary bladder cancer	3.86e-05	0.000359	CcSEcCtD
Prednisone—Decreased appetite—Doxorubicin—urinary bladder cancer	3.82e-05	0.000355	CcSEcCtD
Prednisone—SLCO1A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.8e-05	0.00143	CbGpPWpGaD
Prednisone—Fatigue—Doxorubicin—urinary bladder cancer	3.79e-05	0.000352	CcSEcCtD
Prednisone—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	3.78e-05	0.00142	CbGpPWpGaD
Prednisone—Urticaria—Epirubicin—urinary bladder cancer	3.77e-05	0.000351	CcSEcCtD
Prednisone—Constipation—Doxorubicin—urinary bladder cancer	3.75e-05	0.000349	CcSEcCtD
Prednisone—Body temperature increased—Epirubicin—urinary bladder cancer	3.75e-05	0.000349	CcSEcCtD
Prednisone—Abdominal pain—Epirubicin—urinary bladder cancer	3.75e-05	0.000349	CcSEcCtD
Prednisone—HSD11B1—Metabolism—PTGS2—urinary bladder cancer	3.74e-05	0.00141	CbGpPWpGaD
Prednisone—Hypersensitivity—Methotrexate—urinary bladder cancer	3.74e-05	0.000347	CcSEcCtD
Prednisone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	3.73e-05	0.0014	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—CYP4B1—urinary bladder cancer	3.68e-05	0.00138	CbGpPWpGaD
Prednisone—Asthenia—Methotrexate—urinary bladder cancer	3.64e-05	0.000338	CcSEcCtD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.63e-05	0.00136	CbGpPWpGaD
Prednisone—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.62e-05	0.000337	CcSEcCtD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.61e-05	0.00135	CbGpPWpGaD
Prednisone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.59e-05	0.000334	CcSEcCtD
Prednisone—Pruritus—Methotrexate—urinary bladder cancer	3.59e-05	0.000334	CcSEcCtD
Prednisone—Hypersensitivity—Epirubicin—urinary bladder cancer	3.5e-05	0.000325	CcSEcCtD
Prednisone—Urticaria—Doxorubicin—urinary bladder cancer	3.49e-05	0.000324	CcSEcCtD
Prednisone—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	3.48e-05	0.00131	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—SLC19A1—urinary bladder cancer	3.48e-05	0.0013	CbGpPWpGaD
Prednisone—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	3.47e-05	0.0013	CbGpPWpGaD
Prednisone—Body temperature increased—Doxorubicin—urinary bladder cancer	3.47e-05	0.000323	CcSEcCtD
Prednisone—Abdominal pain—Doxorubicin—urinary bladder cancer	3.47e-05	0.000323	CcSEcCtD
Prednisone—Diarrhoea—Methotrexate—urinary bladder cancer	3.47e-05	0.000323	CcSEcCtD
Prednisone—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	3.42e-05	0.00128	CbGpPWpGaD
Prednisone—Asthenia—Epirubicin—urinary bladder cancer	3.4e-05	0.000317	CcSEcCtD
Prednisone—SLCO1A2—Metabolism—PRSS3—urinary bladder cancer	3.39e-05	0.00127	CbGpPWpGaD
Prednisone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.38e-05	0.00127	CbGpPWpGaD
Prednisone—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	3.38e-05	0.00127	CbGpPWpGaD
Prednisone—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.37e-05	0.00126	CbGpPWpGaD
Prednisone—Pruritus—Epirubicin—urinary bladder cancer	3.36e-05	0.000312	CcSEcCtD
Prednisone—Dizziness—Methotrexate—urinary bladder cancer	3.35e-05	0.000312	CcSEcCtD
Prednisone—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	3.33e-05	0.00125	CbGpPWpGaD
Prednisone—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	3.33e-05	0.00125	CbGpPWpGaD
Prednisone—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	3.33e-05	0.00125	CbGpPWpGaD
Prednisone—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.33e-05	0.00125	CbGpPWpGaD
Prednisone—HSD11B1—Metabolism—PTEN—urinary bladder cancer	3.27e-05	0.00123	CbGpPWpGaD
Prednisone—Diarrhoea—Epirubicin—urinary bladder cancer	3.25e-05	0.000302	CcSEcCtD
Prednisone—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.23e-05	0.000301	CcSEcCtD
Prednisone—Vomiting—Methotrexate—urinary bladder cancer	3.22e-05	0.0003	CcSEcCtD
Prednisone—Rash—Methotrexate—urinary bladder cancer	3.2e-05	0.000297	CcSEcCtD
Prednisone—Dermatitis—Methotrexate—urinary bladder cancer	3.19e-05	0.000297	CcSEcCtD
Prednisone—Headache—Methotrexate—urinary bladder cancer	3.18e-05	0.000295	CcSEcCtD
Prednisone—Asthenia—Doxorubicin—urinary bladder cancer	3.15e-05	0.000293	CcSEcCtD
Prednisone—Dizziness—Epirubicin—urinary bladder cancer	3.14e-05	0.000292	CcSEcCtD
Prednisone—HSD11B1—Metabolism—EP300—urinary bladder cancer	3.11e-05	0.00117	CbGpPWpGaD
Prednisone—Pruritus—Doxorubicin—urinary bladder cancer	3.11e-05	0.000289	CcSEcCtD
Prednisone—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	3.1e-05	0.00116	CbGpPWpGaD
Prednisone—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.09e-05	0.00116	CbGpPWpGaD
Prednisone—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.06e-05	0.00115	CbGpPWpGaD
Prednisone—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.05e-05	0.00115	CbGpPWpGaD
Prednisone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	3.02e-05	0.00113	CbGpPWpGaD
Prednisone—Vomiting—Epirubicin—urinary bladder cancer	3.02e-05	0.000281	CcSEcCtD
Prednisone—Nausea—Methotrexate—urinary bladder cancer	3.01e-05	0.00028	CcSEcCtD
Prednisone—Diarrhoea—Doxorubicin—urinary bladder cancer	3e-05	0.000279	CcSEcCtD
Prednisone—Rash—Epirubicin—urinary bladder cancer	2.99e-05	0.000278	CcSEcCtD
Prednisone—Dermatitis—Epirubicin—urinary bladder cancer	2.99e-05	0.000278	CcSEcCtD
Prednisone—Headache—Epirubicin—urinary bladder cancer	2.97e-05	0.000277	CcSEcCtD
Prednisone—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	2.95e-05	0.00111	CbGpPWpGaD
Prednisone—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	2.95e-05	0.00111	CbGpPWpGaD
Prednisone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.93e-05	0.0011	CbGpPWpGaD
Prednisone—Dizziness—Doxorubicin—urinary bladder cancer	2.9e-05	0.00027	CcSEcCtD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.87e-05	0.00108	CbGpPWpGaD
Prednisone—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	2.86e-05	0.00107	CbGpPWpGaD
Prednisone—ALB—Folate Metabolism—TNF—urinary bladder cancer	2.83e-05	0.00106	CbGpPWpGaD
Prednisone—Nausea—Epirubicin—urinary bladder cancer	2.82e-05	0.000262	CcSEcCtD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.82e-05	0.00106	CbGpPWpGaD
Prednisone—Vomiting—Doxorubicin—urinary bladder cancer	2.79e-05	0.00026	CcSEcCtD
Prednisone—Rash—Doxorubicin—urinary bladder cancer	2.77e-05	0.000258	CcSEcCtD
Prednisone—Dermatitis—Doxorubicin—urinary bladder cancer	2.77e-05	0.000257	CcSEcCtD
Prednisone—Headache—Doxorubicin—urinary bladder cancer	2.75e-05	0.000256	CcSEcCtD
Prednisone—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.75e-05	0.00103	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.72e-05	0.00102	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—TYMP—urinary bladder cancer	2.71e-05	0.00102	CbGpPWpGaD
Prednisone—NR3C1—Adipogenesis—TNF—urinary bladder cancer	2.68e-05	0.00101	CbGpPWpGaD
Prednisone—Nausea—Doxorubicin—urinary bladder cancer	2.61e-05	0.000243	CcSEcCtD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.6e-05	0.000976	CbGpPWpGaD
Prednisone—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	2.57e-05	0.000966	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.5e-05	0.000937	CbGpPWpGaD
Prednisone—ALB—Folate Metabolism—TP53—urinary bladder cancer	2.5e-05	0.000936	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—NAT2—urinary bladder cancer	2.45e-05	0.000919	CbGpPWpGaD
Prednisone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.41e-05	0.000903	CbGpPWpGaD
Prednisone—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	2.32e-05	0.00087	CbGpPWpGaD
Prednisone—ALB—Metabolism—GSTZ1—urinary bladder cancer	2.3e-05	0.000864	CbGpPWpGaD
Prednisone—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.25e-05	0.000844	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.21e-05	0.000828	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.2e-05	0.000824	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.19e-05	0.000821	CbGpPWpGaD
Prednisone—ALB—Metabolism—GSTO2—urinary bladder cancer	2.18e-05	0.000819	CbGpPWpGaD
Prednisone—ALB—Metabolism—NAT1—urinary bladder cancer	2.18e-05	0.000819	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.15e-05	0.000806	CbGpPWpGaD
Prednisone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.15e-05	0.000806	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—RRM2—urinary bladder cancer	2.11e-05	0.000793	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2.07e-05	0.000776	CbGpPWpGaD
Prednisone—Triamcinolone—PTGS2—urinary bladder cancer	2.06e-05	0.232	CrCbGaD
Prednisone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.03e-05	0.000762	CbGpPWpGaD
Prednisone—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	2.02e-05	0.000759	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.02e-05	0.000757	CbGpPWpGaD
Prednisone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2e-05	0.000751	CbGpPWpGaD
Prednisone—ALB—Metabolism—UGT2B7—urinary bladder cancer	2e-05	0.000749	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	1.96e-05	0.000736	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—NAT1—urinary bladder cancer	1.96e-05	0.000736	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—ENO2—urinary bladder cancer	1.96e-05	0.000735	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—HPGDS—urinary bladder cancer	1.96e-05	0.000735	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.95e-05	0.00073	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.93e-05	0.000724	CbGpPWpGaD
Prednisone—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	1.92e-05	0.000721	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.92e-05	0.000719	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.91e-05	0.000718	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.91e-05	0.000718	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—GSTT1—urinary bladder cancer	1.9e-05	0.000713	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.89e-05	0.00071	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.87e-05	0.000702	CbGpPWpGaD
Prednisone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.87e-05	0.0007	CbGpPWpGaD
Prednisone—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.86e-05	0.000697	CbGpPWpGaD
Prednisone—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	1.85e-05	0.000692	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	1.84e-05	0.000691	CbGpPWpGaD
Prednisone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.84e-05	0.00069	CbGpPWpGaD
Prednisone—ALB—Metabolism—CYP4B1—urinary bladder cancer	1.8e-05	0.000675	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	1.79e-05	0.000673	CbGpPWpGaD
Prednisone—SLCO1A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.78e-05	0.000667	CbGpPWpGaD
Prednisone—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	1.77e-05	0.000665	CbGpPWpGaD
Prednisone—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	1.76e-05	0.000661	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.75e-05	0.000657	CbGpPWpGaD
Prednisone—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.71e-05	0.000643	CbGpPWpGaD
Prednisone—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.7e-05	0.000637	CbGpPWpGaD
Prednisone—Betamethasone—PTGS2—urinary bladder cancer	1.69e-05	0.19	CrCbGaD
Prednisone—ALB—Metabolism—PRSS3—urinary bladder cancer	1.66e-05	0.000621	CbGpPWpGaD
Prednisone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.63e-05	0.00061	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	1.61e-05	0.000606	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—ESR2—urinary bladder cancer	1.61e-05	0.000602	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.61e-05	0.000602	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—NQO1—urinary bladder cancer	1.58e-05	0.000592	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.58e-05	0.000591	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.57e-05	0.000589	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.53e-05	0.000575	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	1.52e-05	0.000572	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.49e-05	0.000558	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	1.49e-05	0.000558	CbGpPWpGaD
Prednisone—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.48e-05	0.000554	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.45e-05	0.000544	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.42e-05	0.000532	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.37e-05	0.000515	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.37e-05	0.000514	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.34e-05	0.000501	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.33e-05	0.000498	CbGpPWpGaD
Prednisone—ALB—Metabolism—TYMP—urinary bladder cancer	1.32e-05	0.000496	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	1.32e-05	0.000494	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.31e-05	0.00049	CbGpPWpGaD
Prednisone—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.29e-05	0.000484	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.27e-05	0.000478	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.27e-05	0.000477	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.27e-05	0.000476	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.24e-05	0.000467	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	1.24e-05	0.000465	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	1.22e-05	0.000459	CbGpPWpGaD
Prednisone—ALB—Hemostasis—PLAU—urinary bladder cancer	1.22e-05	0.000456	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.21e-05	0.000454	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.21e-05	0.000454	CbGpPWpGaD
Prednisone—ALB—Metabolism—NAT2—urinary bladder cancer	1.2e-05	0.000449	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.19e-05	0.000447	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.19e-05	0.000446	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.18e-05	0.000442	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.18e-05	0.000442	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	1.17e-05	0.000437	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.16e-05	0.000435	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.16e-05	0.000435	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.14e-05	0.000428	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.14e-05	0.000427	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	1.14e-05	0.000427	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.11e-05	0.000418	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.08e-05	0.000405	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.07e-05	0.000403	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	1.07e-05	0.000401	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.06e-05	0.000398	CbGpPWpGaD
Prednisone—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.05e-05	0.000395	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.05e-05	0.000394	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000393	CbGpPWpGaD
Prednisone—ALB—Metabolism—RRM2—urinary bladder cancer	1.03e-05	0.000388	CbGpPWpGaD
Prednisone—ALB—Hemostasis—CREBBP—urinary bladder cancer	1e-05	0.000377	CbGpPWpGaD
Prednisone—ALB—Hemostasis—IGF1—urinary bladder cancer	9.91e-06	0.000372	CbGpPWpGaD
Prednisone—Dexamethasone—PTGS2—urinary bladder cancer	9.82e-06	0.111	CrCbGaD
Prednisone—NR3C1—Gene Expression—ESR1—urinary bladder cancer	9.74e-06	0.000365	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.71e-06	0.000364	CbGpPWpGaD
Prednisone—ALB—Metabolism—ENO2—urinary bladder cancer	9.57e-06	0.000359	CbGpPWpGaD
Prednisone—ALB—Metabolism—HPGDS—urinary bladder cancer	9.57e-06	0.000359	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.51e-06	0.000357	CbGpPWpGaD
Prednisone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.34e-06	0.000351	CbGpPWpGaD
Prednisone—ALB—Metabolism—GSTT1—urinary bladder cancer	9.28e-06	0.000348	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—RRM2—urinary bladder cancer	9.27e-06	0.000348	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	9.17e-06	0.000344	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.14e-06	0.000343	CbGpPWpGaD
Prednisone—ALB—Hemostasis—RHOA—urinary bladder cancer	9.08e-06	0.000341	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—RRM2—urinary bladder cancer	9.05e-06	0.00034	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.93e-06	0.000335	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—PPARG—urinary bladder cancer	8.88e-06	0.000333	CbGpPWpGaD
Prednisone—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.69e-06	0.000326	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	8.67e-06	0.000325	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	8.59e-06	0.000322	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—ENO2—urinary bladder cancer	8.59e-06	0.000322	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.54e-06	0.00032	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	8.53e-06	0.00032	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—ENO2—urinary bladder cancer	8.38e-06	0.000315	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	8.38e-06	0.000315	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	8.33e-06	0.000313	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	8.33e-06	0.000312	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.2e-06	0.000308	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	8.13e-06	0.000305	CbGpPWpGaD
Prednisone—ALB—Metabolism—NQO1—urinary bladder cancer	7.71e-06	0.000289	CbGpPWpGaD
Prednisone—ALB—Hemostasis—IL2—urinary bladder cancer	7.62e-06	0.000286	CbGpPWpGaD
Prednisone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.61e-06	0.000286	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.48e-06	0.000281	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.14e-06	0.000268	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	6.92e-06	0.00026	CbGpPWpGaD
Prednisone—ALB—Hemostasis—EP300—urinary bladder cancer	6.83e-06	0.000256	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	6.82e-06	0.000256	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.76e-06	0.000254	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.72e-06	0.000252	CbGpPWpGaD
Prednisone—ALB—Hemostasis—SRC—urinary bladder cancer	6.65e-06	0.000249	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.52e-06	0.000245	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.46e-06	0.000242	CbGpPWpGaD
Prednisone—ALB—Metabolism—GSTP1—urinary bladder cancer	6.43e-06	0.000241	CbGpPWpGaD
Prednisone—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.22e-06	0.000233	CbGpPWpGaD
Prednisone—ALB—Metabolism—TYMS—urinary bladder cancer	5.98e-06	0.000224	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	5.95e-06	0.000223	CbGpPWpGaD
Prednisone—ALB—Metabolism—GSTM1—urinary bladder cancer	5.91e-06	0.000222	CbGpPWpGaD
Prednisone—ALB—Metabolism—NCOR1—urinary bladder cancer	5.91e-06	0.000222	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.86e-06	0.00022	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	5.77e-06	0.000217	CbGpPWpGaD
Prednisone—SLCO1A2—Metabolism—EP300—urinary bladder cancer	5.67e-06	0.000213	CbGpPWpGaD
Prednisone—ALB—Metabolism—GPX1—urinary bladder cancer	5.66e-06	0.000212	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.63e-06	0.000211	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.59e-06	0.00021	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.58e-06	0.000209	CbGpPWpGaD
Prednisone—ALB—Metabolism—ERCC2—urinary bladder cancer	5.56e-06	0.000208	CbGpPWpGaD
Prednisone—ALB—Hemostasis—KRAS—urinary bladder cancer	5.5e-06	0.000206	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	5.37e-06	0.000201	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	5.31e-06	0.000199	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	5.31e-06	0.000199	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.24e-06	0.000197	CbGpPWpGaD
Prednisone—ALB—Metabolism—MTHFR—urinary bladder cancer	5.22e-06	0.000196	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.18e-06	0.000194	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.18e-06	0.000194	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.16e-06	0.000194	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.16e-06	0.000194	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	5.08e-06	0.000191	CbGpPWpGaD
Prednisone—NR3C1—Gene Expression—MYC—urinary bladder cancer	5.06e-06	0.00019	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.01e-06	0.000188	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	4.99e-06	0.000187	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.96e-06	0.000186	CbGpPWpGaD
Prednisone—ALB—Hemostasis—TP53—urinary bladder cancer	4.89e-06	0.000184	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.87e-06	0.000183	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	4.69e-06	0.000176	CbGpPWpGaD
Prednisone—ALB—Hemostasis—HRAS—urinary bladder cancer	4.68e-06	0.000176	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.58e-06	0.000172	CbGpPWpGaD
Prednisone—ALB—Metabolism—PPARG—urinary bladder cancer	4.24e-06	0.000159	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.16e-06	0.000156	CbGpPWpGaD
Prednisone—ALB—Metabolism—CREBBP—urinary bladder cancer	4.07e-06	0.000153	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	3.8e-06	0.000143	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.71e-06	0.000139	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	3.65e-06	0.000137	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.56e-06	0.000134	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.47e-06	0.00013	CbGpPWpGaD
Prednisone—ALB—Metabolism—PTGS2—urinary bladder cancer	3.33e-06	0.000125	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.23e-06	0.000121	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.19e-06	0.00012	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.19e-06	0.00012	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.06e-06	0.000115	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3e-06	0.000113	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.99e-06	0.000112	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.92e-06	0.00011	CbGpPWpGaD
Prednisone—ALB—Metabolism—PTEN—urinary bladder cancer	2.91e-06	0.000109	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.82e-06	0.000106	CbGpPWpGaD
Prednisone—ALB—Metabolism—EP300—urinary bladder cancer	2.77e-06	0.000104	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	2.61e-06	9.79e-05	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.55e-06	9.55e-05	CbGpPWpGaD
Prednisone—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.49e-06	9.33e-05	CbGpPWpGaD
Prednisone—ABCB1—Metabolism—EP300—urinary bladder cancer	2.43e-06	9.11e-05	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.29e-06	8.58e-05	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.2e-06	8.24e-05	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.8e-06	6.75e-05	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.57e-06	5.89e-05	CbGpPWpGaD
Prednisone—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.5e-06	5.61e-05	CbGpPWpGaD
